Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1? mAb, to Treat Hidradenitis Suppurativa

Stock Information for Avalo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avalo Therapeutics Inc.

Avalo Announces Participation in September Investor Conferences
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Avalo Reports 2023 Financial Results and Provides Business Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.